Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer

Jianfeng Zhu; Yanyan Yu; Jiaqi Mei; Shiyao Chen; Jiufei Li; Sicong Jiang

doi:10.3389/fimmu.2023.1278573

Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer

Front Immunol. 2023 Dec 6:14:1278573. doi: 10.3389/fimmu.2023.1278573. eCollection 2023.

Authors

Jianfeng Zhu¹, Yanyan Yu², Jiaqi Mei³, Shiyao Chen⁴, Jiufei Li⁵, Sicong Jiang⁶

Affiliations

¹ Department of Thoracic Surgery, Jiangxi Province Cancer Hospital, Nanchang, Jiangxi, China.
² Department of Operation Room, Jiangxi Province Cancer hospital, Nanchang, Jiangxi, China.
³ College of Innovation and Entrepreneurship, The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
⁴ Department of Clinical Medicine, Jiangxi Institute of Applied Science and Technology, Nanchang, Jiangxi, China.
⁵ Department of Thoracic Surgery, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, China.
⁶ Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, Geneva, Switzerland.

Abstract

Background: The clinical efficacy and safety of camrelizumab as a third- or later-line regimen in patients with advanced non-small cell lung cancer (NSCLC) have not been determined in large clinical trials.

Objective: This study aimed to evaluate the clinical efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel as a third- or later-line treatment for patients with advanced NSCLC.

Methods: A total of 257 patients with advanced NSCLC who were histopathologically confirmed and failed in clinical second-line therapy regimens at Jiangxi Province Cancer hospital from January 2018 to December 2021 were retrospectively selected. Patients with advanced NSCLC were divided into the single treatment group (STG) of camrelizumab, and the combined treatment group (CTG) of camrelizumab in combination with albumin-bound paclitaxel according to the treatment regimen. The primary outcomes of interest were clinical efficacy[objective response rate (ORR) and disease control rate (DCR)], progression-free survival (PFS), and overall survival (OS). Survival data were analyzed using the Kaplan-Meier method, and the log-rank test was performed. Additionally, Cox proportional hazard regression was used to analyze the correlation of prognosis and baseline characteristics between subgroups, to identify the potential independent risk factors for PFS and OS. Furthermore, the occurrence of side effects was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE 4.03).

Results: Of the 257 patients with advanced NSCLC included in the research, 135 patients received camrelizumab, and 122 patients received camrelizumab plus albumin-bound paclitaxel. The ORR of CTG and STG was 59.84% and 50.38%, and the DCR was 77.05% and 65.93%, respectively. The median PFS in CTG was higher than that in the STG (5.27 vs. 3.57 months, P = 0.0074), and the median OS was longer (7.09 vs. 6.47 months, P < 0.01). The lines of treatment, metastases, and PD-L1 expression levels were independent risk factors for the mPFS and mOS of patients with advanced NSCLC. The occurrence of adverse events was similar between camrelizumab and camrelizumab plus albumin-bound paclitaxel groups.

Conclusion: Camrelizumab combined with albumin-bound paclitaxel as the third- or later-line regimen greatly prolonged PFS and OS of advanced NSCLC patients. A prospective clinical trial is warranted.

Keywords: advanced; albumin-bound paclitaxel; camrelizumab; non-small cell lung cancer; third- or later-line treatment.

MeSH terms

Albumin-Bound Paclitaxel
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Prospective Studies
Retrospective Studies

Substances

Albumin-Bound Paclitaxel
camrelizumab

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. No external funding received to conduct this study.